A new treatment is offering hope for women with hard-to-treat ovarian cancer.
Mirvetuximab soravtansine, a targeted "Trojan horse" therapy, has been shown to extend survival and delay disease progression in patients who have stopped responding to chemotherapy.
www.emjreviews.com/general-heal...
The ovarian cancer drug mirvetuximab soravtansine extends survival in NHS patients with platinum-resistant disease using targeted therapy.
